Core for Life - a new European alliance in biomedical research: http://t.co/Hvv6P88kRt
FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.
Opening of new laboratories on the Waterfront science park in Niel, Belgium Multiplicom nv, specialized in the development, production and commercialization of innovative molecular genetic tests, announces that it launches two new kits for cancer predisposition screening based on its Multiplexer™-technology. Concurrently the company will on September 23rd officially open its brand new laboratories on the Waterfront science park in Niel, Belgium.
The newly developed tests allow, starting from a DNA sample, to determine if somebody has an increased risk to develop colon cancer. A first test identifies mutations that may lead to the development of Familiar Adenomatous Polyposis (FAP) whereby at young age a large number of polyps develop in the gut that may lead to colon cancer. A second test identifies mutations that may lead to the development of Hereditary Non-Polyposis Colorectal Carcinoma (HNPCC) or the Lunch-syndrome, a hereditary form of colon cancer. Individuals with HNPCC have an 80% chance to develop colon cancer during their life. Early diagnosis of these hereditary diseases is very important so that these patients can undergo preventive examinations such that the disease can be detected early, at a stage where it is still treatable.
Multiplicom’s new laboratories at the Waterfront science park in Niel have a total surface of 250 m2. Besides the laboratories, Multiplicom has also the necessary office and storage space.
“The capital increase by Gimv, VIB and UA have allowed us to focus on the increasing demand by our customers for new genetic predisposition tests. The new FAP- and HNPCC-kits are the first results thereof” explains Dirk Pollet, CEO of Multiplicom. “Our team is particularly satisfied with the new laboratories, that should allow us to develop and produce high value CE-labeled diagnostic products” says Chief Technology Officer Jurgen Del-Favero.